ProCE Banner Activity

Treatment Paradigm Disruption With 2-Drug Regimens: Insights From IDWeek 2021

Conference Coverage
Clinical Thought
New 2-drug regimen strategies for people with HIV have disrupted the traditional treatment paradigm of 3-drug regimens. Read my take on what these data from IDWeek 2021 mean for practice in Western Europe.

Released: November 02, 2021

Expiration: November 01, 2022

No longer available for credit.

Share

Faculty

Karine Lacombe

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from Gilead Sciences, MSD, and ViiV Healthcare and has received other financial or material support from Chiesi, Gilead Sciences, MSD, and ViiV Healthcare.